Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-20-286837
Filing Date
2020-11-05
Accepted
2020-11-05 16:15:44
Documents
62
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q d943246d10q.htm   iXBRL 10-Q 1751935
2 EX-31.1 d943246dex311.htm EX-31.1 10740
3 EX-31.2 d943246dex312.htm EX-31.2 10718
4 EX-32.1 d943246dex321.htm EX-32.1 5805
  Complete submission text file 0001193125-20-286837.txt   6074225

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA gbt-20200930.xsd EX-101.SCH 38492
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE gbt-20200930_cal.xml EX-101.CAL 44928
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE gbt-20200930_def.xml EX-101.DEF 182489
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE gbt-20200930_lab.xml EX-101.LAB 379506
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gbt-20200930_pre.xml EX-101.PRE 307620
10 EXTRACTED XBRL INSTANCE DOCUMENT d943246d10q_htm.xml XML 921343
Mailing Address 181 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080
Business Address 181 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080 650741-7700
Global Blood Therapeutics, Inc. (Filer) CIK: 0001629137 (see all company filings)

EIN.: 274825712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37539 | Film No.: 201290641
SIC: 2834 Pharmaceutical Preparations